Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298

Fraser P. Coxon, Miep H. Helfrich, Robert Van't Hof, Saïd Sebti, Stuart H. Ralston, Andrew Hamilton, Michael J. Rogers

Research output: Contribution to journalArticle

Abstract

Bisphosphonates are the important class of antiresorptive drugs used in the treatment of metabolic bone diseases. Although their molecular mechanism of action has not been fully elucidated, recent studies have shown that the nitrogen-containing bisphosphonates can inhibit protein prenylation in macrophages in vitro. In this study, we show that the nitrogen-containing bisphosphonates risedronate, zoledronate, ibandronate, alendronate, and pamidronate (but not the non nitrogen-containing bisphosphonates clodronate, etidronate, and tiludronate) prevent the incorporation of [14C]mevalonate into prenylated (farnesylated and geranylgeranylated) proteins in purified rabbit osteoclasts. The inhibitory effect of nitrogen-containing bisphosphonates on bone resorption is likely to result largely from the loss of geranylgeranylated proteins rather than loss of farnesylated proteins in osteoclasts, because concentrations of GGTI-298 (a specific inhibitor of geranylgeranyl transferase I) that inhibited protein geranylgeranylation in purified rabbit osteoclasts prevented osteoclast formation in murine bone marrow cultures, disrupted the osteoclast cytoskeleton, inhibited bone resorption, and induced apoptosis in isolated chick and rabbit osteoclasts in vitro. By contrast, concentrations of FTI-277 (a specific inhibitor of farnesyl transferase) that prevented protein farnesylation in purified rabbit osteoclasts had little effect on osteoclast morphology or apoptosis and did not inhibit bone resorption. These results therefore show the molecular mechanism of action of nitrogen-containing bisphosphonate drugs in osteoclasts and highlight the fundamental importance of geranylgeranylated proteins in osteoclast formation and function.

Original languageEnglish (US)
Pages (from-to)1467-1476
Number of pages10
JournalJournal of Bone and Mineral Research
Volume15
Issue number8
StatePublished - 2000

Fingerprint

Protein Prenylation
Diphosphonates
Osteoclasts
Nitrogen
Bone Resorption
Rabbits
zoledronic acid
pamidronate
Transferases
Proteins
GGTI 298
Bone Density Conservation Agents
Etidronic Acid
Clodronic Acid
Apoptosis
Alendronate
Mevalonic Acid
Metabolic Bone Diseases
Cytoskeleton
Bone Marrow

Keywords

  • Apoptosis
  • Bisphosphonate
  • Mevalonate
  • Osteoclast
  • Prenylation

ASJC Scopus subject areas

  • Surgery

Cite this

Protein geranylgeranylation is required for osteoclast formation, function, and survival : Inhibition by bisphosphonates and GGTI-298. / Coxon, Fraser P.; Helfrich, Miep H.; Van't Hof, Robert; Sebti, Saïd; Ralston, Stuart H.; Hamilton, Andrew; Rogers, Michael J.

In: Journal of Bone and Mineral Research, Vol. 15, No. 8, 2000, p. 1467-1476.

Research output: Contribution to journalArticle

Coxon, Fraser P. ; Helfrich, Miep H. ; Van't Hof, Robert ; Sebti, Saïd ; Ralston, Stuart H. ; Hamilton, Andrew ; Rogers, Michael J. / Protein geranylgeranylation is required for osteoclast formation, function, and survival : Inhibition by bisphosphonates and GGTI-298. In: Journal of Bone and Mineral Research. 2000 ; Vol. 15, No. 8. pp. 1467-1476.
@article{91f1ba279cc84dfeba43ef8b8460c046,
title = "Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298",
abstract = "Bisphosphonates are the important class of antiresorptive drugs used in the treatment of metabolic bone diseases. Although their molecular mechanism of action has not been fully elucidated, recent studies have shown that the nitrogen-containing bisphosphonates can inhibit protein prenylation in macrophages in vitro. In this study, we show that the nitrogen-containing bisphosphonates risedronate, zoledronate, ibandronate, alendronate, and pamidronate (but not the non nitrogen-containing bisphosphonates clodronate, etidronate, and tiludronate) prevent the incorporation of [14C]mevalonate into prenylated (farnesylated and geranylgeranylated) proteins in purified rabbit osteoclasts. The inhibitory effect of nitrogen-containing bisphosphonates on bone resorption is likely to result largely from the loss of geranylgeranylated proteins rather than loss of farnesylated proteins in osteoclasts, because concentrations of GGTI-298 (a specific inhibitor of geranylgeranyl transferase I) that inhibited protein geranylgeranylation in purified rabbit osteoclasts prevented osteoclast formation in murine bone marrow cultures, disrupted the osteoclast cytoskeleton, inhibited bone resorption, and induced apoptosis in isolated chick and rabbit osteoclasts in vitro. By contrast, concentrations of FTI-277 (a specific inhibitor of farnesyl transferase) that prevented protein farnesylation in purified rabbit osteoclasts had little effect on osteoclast morphology or apoptosis and did not inhibit bone resorption. These results therefore show the molecular mechanism of action of nitrogen-containing bisphosphonate drugs in osteoclasts and highlight the fundamental importance of geranylgeranylated proteins in osteoclast formation and function.",
keywords = "Apoptosis, Bisphosphonate, Mevalonate, Osteoclast, Prenylation",
author = "Coxon, {Fraser P.} and Helfrich, {Miep H.} and {Van't Hof}, Robert and Sa{\"i}d Sebti and Ralston, {Stuart H.} and Andrew Hamilton and Rogers, {Michael J.}",
year = "2000",
language = "English (US)",
volume = "15",
pages = "1467--1476",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Protein geranylgeranylation is required for osteoclast formation, function, and survival

T2 - Inhibition by bisphosphonates and GGTI-298

AU - Coxon, Fraser P.

AU - Helfrich, Miep H.

AU - Van't Hof, Robert

AU - Sebti, Saïd

AU - Ralston, Stuart H.

AU - Hamilton, Andrew

AU - Rogers, Michael J.

PY - 2000

Y1 - 2000

N2 - Bisphosphonates are the important class of antiresorptive drugs used in the treatment of metabolic bone diseases. Although their molecular mechanism of action has not been fully elucidated, recent studies have shown that the nitrogen-containing bisphosphonates can inhibit protein prenylation in macrophages in vitro. In this study, we show that the nitrogen-containing bisphosphonates risedronate, zoledronate, ibandronate, alendronate, and pamidronate (but not the non nitrogen-containing bisphosphonates clodronate, etidronate, and tiludronate) prevent the incorporation of [14C]mevalonate into prenylated (farnesylated and geranylgeranylated) proteins in purified rabbit osteoclasts. The inhibitory effect of nitrogen-containing bisphosphonates on bone resorption is likely to result largely from the loss of geranylgeranylated proteins rather than loss of farnesylated proteins in osteoclasts, because concentrations of GGTI-298 (a specific inhibitor of geranylgeranyl transferase I) that inhibited protein geranylgeranylation in purified rabbit osteoclasts prevented osteoclast formation in murine bone marrow cultures, disrupted the osteoclast cytoskeleton, inhibited bone resorption, and induced apoptosis in isolated chick and rabbit osteoclasts in vitro. By contrast, concentrations of FTI-277 (a specific inhibitor of farnesyl transferase) that prevented protein farnesylation in purified rabbit osteoclasts had little effect on osteoclast morphology or apoptosis and did not inhibit bone resorption. These results therefore show the molecular mechanism of action of nitrogen-containing bisphosphonate drugs in osteoclasts and highlight the fundamental importance of geranylgeranylated proteins in osteoclast formation and function.

AB - Bisphosphonates are the important class of antiresorptive drugs used in the treatment of metabolic bone diseases. Although their molecular mechanism of action has not been fully elucidated, recent studies have shown that the nitrogen-containing bisphosphonates can inhibit protein prenylation in macrophages in vitro. In this study, we show that the nitrogen-containing bisphosphonates risedronate, zoledronate, ibandronate, alendronate, and pamidronate (but not the non nitrogen-containing bisphosphonates clodronate, etidronate, and tiludronate) prevent the incorporation of [14C]mevalonate into prenylated (farnesylated and geranylgeranylated) proteins in purified rabbit osteoclasts. The inhibitory effect of nitrogen-containing bisphosphonates on bone resorption is likely to result largely from the loss of geranylgeranylated proteins rather than loss of farnesylated proteins in osteoclasts, because concentrations of GGTI-298 (a specific inhibitor of geranylgeranyl transferase I) that inhibited protein geranylgeranylation in purified rabbit osteoclasts prevented osteoclast formation in murine bone marrow cultures, disrupted the osteoclast cytoskeleton, inhibited bone resorption, and induced apoptosis in isolated chick and rabbit osteoclasts in vitro. By contrast, concentrations of FTI-277 (a specific inhibitor of farnesyl transferase) that prevented protein farnesylation in purified rabbit osteoclasts had little effect on osteoclast morphology or apoptosis and did not inhibit bone resorption. These results therefore show the molecular mechanism of action of nitrogen-containing bisphosphonate drugs in osteoclasts and highlight the fundamental importance of geranylgeranylated proteins in osteoclast formation and function.

KW - Apoptosis

KW - Bisphosphonate

KW - Mevalonate

KW - Osteoclast

KW - Prenylation

UR - http://www.scopus.com/inward/record.url?scp=0033930168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033930168&partnerID=8YFLogxK

M3 - Article

C2 - 10934645

AN - SCOPUS:0033930168

VL - 15

SP - 1467

EP - 1476

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 8

ER -